MDS Alliance’s Post

We are thrilled to announce another significant breakthrough in Ryvu's history. The first patient has been dosed with the study drugs in the Phase II clinical trial investigating RVU120 in combination with venetoclax. The primary goal of the RIVER-81 study is to evaluate the safety and efficacy of RVU120 in combination with venetoclax in a population of relapsed/refractory acute myeloid leukemia patients who have failed prior venetoclax treatment and a hypomethylating agent.   We are excited to embark on this clinical journey and contribute to the advancement of treatment options for cancer patients.   Read more: https://lnkd.in/dh5CcvwT #RVU120 #AML #CombinationTheraphy #Venetoclax

📝 Who not to treat? When and how long to treat? How can toxicity be reduced and effectiveness maintained or even improved? These are some of the questions that treatment optimisation research aims to answer. Last month we gathered in Amsterdam for the Cancer Medicines Forum workshop, organised in collaboration with the European Medicines Agency and under the auspices of the Belgian Presidency of the Council of the European Union 2024. The workshop provided an opportunity to discuss the current status and next steps of treatment optimisation research, emphasising the importance of independent clinical research organisations such as EORTC in determining the optimal use of anticancer medicines. Read the article to delve into the key insights from the workshop: https://lnkd.in/dU_q4sgb #CancerResearch #ClinicalTrials #Oncology #EuropeanMedicinesAgency #CancerMedicinesForum #TreatmentOptimisation

🚨 Breaking News 🚨 On July 26th, 2024, the National Comprehensive Cancer Network (NCCN) updated its Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes (MDS). RYTELO™ (imetelstat) is now recommended as a Category 1 and 2A treatment for symptomatic anemia in patients with lower-risk MDS. These updates to the MDS NCCN Guidelines follow the U.S. FDA’s approval in June 2024 of RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk MDS with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to, have lost response to, or are ineligible for erythropoiesis-stimulating agents (ESAs). This is a significant advancement in MDS treatment. Read the full press release: https://bit.ly/3WkDT9I #MDSJourney #MDSTreatment #Innovation #MedicalAdvancement #HopeForMDS

American Society of Clinical Oncology (ASCO) now recommends #universal #germline #genetictesting for all #patients w/ #breastcancer <=65yrs c/w Peter Beitsch MD et al. https://lnkd.in/gp_y-we #JCO American Society of Clinical Oncology (ASCO), Invitae & Pat Whitworth et al. https://lnkd.in/eDKzMT-x JAMA Network Open, Invitae A strong step in the right direction (leading National Comprehensive Cancer Network® (NCCN®)), need only to also offer #genetictesting to all #patients >65yrs...why should they not receive benefits from #precisiontherapy & #clinicaltrials afforded by #universal #germlinetesting simply 2/2 increased age #access #reducedisparities #precisionmedicine #precisionprevention https://lnkd.in/gZU8Vuan

As September is Blood Cancer Awareness Month, we at FORUS Therapeutics want to raise awareness for the growing prevalence of this incurable blood cancer in Canada. Compared to other cancers, the incidence rate of multiple myeloma in males has been increasing in females since 2005 and increasing in males since 2007, at 2.5% and 1.6% per year, respectively.   We must continue to raise awareness, invest in research, and support patients and caregivers. Together, we can work toward improving diagnosis, treatment options, and ultimately, the quality of life for those living with multiple myeloma.   #bloodcancerawarenessmonth #bloodcancerawareness #multiplemyeloma #patients               

At present, treating high-risk patients with #TP53-mutated #myeloid #malignancies remains an area of unmet need 🤔 In an interview from #ASCO24, David Sallman, MD, Moffitt Cancer Center, discusses updates in this area 🎥 🩸 Trials with #eprenetapopt (APR-246) and #magrolimab have been unsuccessful, leaving frontline treatment for these high-risk patients an unmet need Ongoing Phase III trials are investigating #venetoclax (VERONA; NCT04401748) and #tamibarotene 💡 Additionally, novel combinations, new anti-#CD47 agents, and weekly dosing schedules are being explored to improve outcomes Learn more 👉 https://lnkd.in/dA6FhSTf #VJHemOnc #Hematologynews

𝐂𝐨𝐮𝐥𝐝 𝐅𝐑𝐔𝐙𝐀𝐐𝐋𝐀™ 𝐫𝐞𝐝𝐞𝐟𝐢𝐧𝐞 𝐦𝐂𝐑𝐂 𝐭𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭? Takeda's new release, #FRUZAQLA, marks a pivotal shift in metastatic colorectal cancer care. As the first oral therapy targeting all three VEGF receptor kinases, it promises a novel approach for patients who have exhausted other options. The edge? FRUZAQLA™ demonstrated significant gains in both overall and progression-free survival against placebos in Phase 3 trials. This is a new direction for patient care. Why pivot to FRUZAQLA™ now? It offers a chemotherapy-free alternative, crucial for enhancing quality of life in mCRC treatments. This positions FRUZAQLA™ not just as a medication, but as a cornerstone in modern oncology strategies. How will FRUZAQLA™ fit into your current treatment landscape? Share your thoughts! 𝐏.𝐒. 𝐃𝐨𝐧'𝐭 𝐟𝐨𝐫𝐠𝐞𝐭 𝐭𝐨 𝐫𝐞𝐩𝐨𝐬𝐭 ♻️ 𝐭𝐡𝐢𝐬 𝐟𝐨𝐫 𝐨𝐭𝐡𝐞𝐫𝐬. #Cancer #Oncology #Oncolyst #ColorectalCancer 𝐍𝐨𝐭𝐞: This is for education purpose. Please consult your doctor before opting for any treatment.

The current treatment landscape for OM is characterised by lack of standardized, effective, well-tolerated and safe options. In particular the pain associated with OM continues to represent a significant unmet medical need as it affects patients on multiple levels, including impaired psychological and physical quality of life, and adverse effects on their cancer treatment and hence, potentially, survival. We aim to adress this unmet need. #Oralmucositis #Cancer #Headandneckcancer #HNcancerawarenessmonth #Oralpain #REDUCEOPIOIDUSE Follow our Journey below.

Resistance to EGFR inhibitors remains a formidable obstacle in lung cancer treatment, thwarting therapeutic efforts and diminishing patient outcomes. In this editorial, we dissect the underlying mechanisms of resistance, emphasizing the urgency for innovative solutions to address this pressing clinical dilemma. #fightinglungcancer #EGFRinhibitors #nextgenerationtherapy

Follow our Journey with BupiZenge targeting Oral mucositis pain!